NYSE:NVS - Novartis Stock Price, Forecast & News

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis declared an annual dividend on Thursday, January 31st. Shareholders of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a dividend yield of 3.27%. The ex-dividend date of this dividend is Monday, March 4th. This is an increase from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.

Novartis AG (NYSE:NVS) posted its earnings results on Tuesday, October, 22nd. The company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.31 by $0.10. The company earned $12.17 billion during the quarter, compared to analysts' expectations of $11.67 billion. Novartis had a net margin of 24.43% and a return on equity of 20.86%. The firm's revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.32 EPS. View Novartis' Earnings History.

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Novartis.

Novartis will be holding an earnings conference call on Wednesday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 Wall Street analysts have issued 1-year price objectives for Novartis' stock. Their forecasts range from $79.16 to $105.00. On average, they anticipate Novartis' stock price to reach $91.67 in the next twelve months. This suggests that the stock has a possible downside of 2.3%. View Analyst Price Targets for Novartis.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

News headlines about NVS stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novartis earned a news impact score of -4.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Novartis.

Novartis saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,100,000 shares, a drop of 11.7% from the December 15th total of 3,510,000 shares. Based on an average daily volume of 1,560,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 0.1% of the company's stock are short sold. View Novartis' Current Options Chain.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), AbbVie (ABBV), AT&T (T), Pfizer (PFE), NVIDIA (NVDA), Cisco Systems (CSCO), Intel (INTC), Merck & Co., Inc. (MRK) and Verizon Communications (VZ).

Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.09%), Bristol John W & Co. Inc. NY (0.03%), Welch Group LLC (0.01%), Country Trust Bank (0.01%), Tocqueville Asset Management L.P. (0.01%) and Janney Montgomery Scott LLC (0.01%).

NVS stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Tocqueville Asset Management L.P., Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Country Trust Bank, GFS Advisors LLC, Commerzbank Aktiengesellschaft FI, Howland Capital Management LLC and Scout Investments Inc..

NVS stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, Mckinley Capital Management LLC Delaware, Advisors Capital Management LLC, Campbell & CO Investment Adviser LLC, Ingalls & Snyder LLC, Janney Montgomery Scott LLC, Smithbridge Asset Management Inc. DE and AdvisorShares Investments LLC.

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $93.87.

Novartis has a market capitalization of $215.13 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis.

The official website for Novartis is http://www.novartis.com/.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]